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ABSTRACT
Background: Trade-offs between costs and outcomes are a reality of
health-care decisions. Cost-effectiveness analyses can guide choices toward
interventions with the most health beneﬁt for the least cost but are limited
because generic measures of health value are infrequently available in the
literature and are expensive to collect.
Objective: We report on the application of a new approach to estimate the
health value of alternative treatment patterns. We apply this approach to
common treatment patterns for major depression, and we generate esti-
mates of the change in health value that is attributable to a particular
treatment. We also obtain estimates of treatment costs and report cost/
health value ratios. We used a modiﬁed expert panel approach to estimate
the change in health value attributable to different patterns of treatment.We
used claims and pharmacy data to deﬁne usual care treatment patterns and
estimate costs.
Results: The lowest cost and most frequent treatment, 1 to 3 psycho-
therapy visits, produces minimal improvement. Treatments that include an
antidepressant medication provide more health beneﬁt per unit cost than
all other treatments and adding a medication follow-up visit provides a lot
of beneﬁt for minimal cost.
Conclusions: We demonstrate the application of a new approach to esti-
mate the health value of common depression treatment practices in the
United States. Our results suggest cost-effective targets for quality
improvement efforts by identifying ways in which treatment for depression
could cost less to get to a given outcome. Because our approach uses a
generic health outcome measure, it can be applied to other conditions,
permitting comparisons of beneﬁt across diseases.
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Introduction
Trade-offs between costs and outcomes are inherent in making
health-care decisions, but clinicians, administrators, and policy-
makers have little information to guide these trade-offs. Clini-
cians make decisions about alternative treatments and which
components of treatment to emphasize given limited time with
patients, administrators make decisions about where to focus
quality improvement efforts, and policymakers and insurers
make decisions about which treatments should be reimbursed or
encouraged with ﬁnancial incentives. All of these decisions
involve trade-offs between costs and outcomes, trade-offs that
are difﬁcult to make explicit.
Treatment guidelines can help, but are inadequate to guide
many health-care decisions. First, although some health authori-
ties are increasingly taking economics into account, guidelines
seldom refer to the costs of treatment, and thus the relative
cost-effectiveness of alternative treatment approaches. The
efﬁciency of health care—getting the best value for health
expenditures—is an increasingly crucial concern of administra-
tors, policymakers, insurers, and payers. Second, guidelines do
not inform us about the clinical beneﬁt of common practice
patterns that are not consistent with guidelines. Because the gap
between recommended care and usual care is well documented
[1], knowing the costs and beneﬁts of commonly delivered treat-
ment patterns would inform resource allocation decisions made
in real world settings and identify speciﬁc targets for quality
improvement efforts based on potential increments in system-
wide cost-effectiveness.
Cost-effectiveness analyses (CEA) can show the trade-offs
involved in choosing among different treatments. When out-
comes are measured using a generic scale such as health-related
quality of life or utilities, the cost and beneﬁts (value) of different
treatments across diseases can be compared. Utilities have a
strong theoretical basis and have been used to rate the magnitude
of health beneﬁt in CEA [2]. The major limitation of using
utilities is that utility ratings are infrequently available in the
literature and are expensive and time-consuming to collect.
Although a growing body of literature reports cost-effectiveness
ratios associated with clinical trials (CEA Registry citation),
many common clinical practices have not been evaluated in such
trials, and extrapolation of results from clinical samples to the
diversity of patients in usual care is not straightforward.
In this article, we report the costs and effectiveness of
common depression treatment practices in the United States
observed in usual care. We obtained effectiveness estimates based
on a new approach in which expert panelists rate the beneﬁt of
alternative treatment patterns using a visual analog scale. In this
method, “health value” captures the same concept as gains in
utilities associated with treatment. Expert ratings were made
using the commonly employed magnitude rating scale to repre-
sent health utilities (where 0 represents death and 1 represents
best possible health), and series of rating tasks elicited estimates
of changes in patient health states over time with and without
treatment. We applied this approach to common treatment pat-
terns and patient characteristics found in usual care for major
depression, and we generate estimates of the change in health
value that is directly attributable to a particular treatment
pattern. We also obtain estimates of the costs of each treatment
and report cost/health value ratios. We anticipate these results
will be helpful to clinicians, administrators, and policymakers
who are making trade-offs between health-care costs and
outcomes.
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We selected major depression in adults because it is common,
has published practice guidelines, and the gap between recom-
mended and usual care is large [3–8]. Among those in treatment
for major depression, medication dose and duration is often
lower than recommended; and the number of psychotherapy
visits received is far fewer than provided in clinical trials
demonstrating the effectiveness of speciﬁc psychotherapeutic
approaches. Several studies suggest that quality of care for
depression can be improved [9–13] and provide a mechanism for
translating our results into improved care for depression.
Methods
Overview
We used expert panelists to elicit utility ratings for deﬁned patient
groups before and after treatment [14,15]. A panel 13 clinical
experts made a series of utility ratings for a range of clinical
proﬁles before any new treatment, 3 months later with no new
treatment and 3 months after initiating various common treat-
ments. The clinical proﬁles speciﬁed characteristics of patient
groups, treatments to be rated, and their combinations. The
treatment beneﬁt for each proﬁle was estimated by calculating
the difference between the before and after treatment utility
ratings. Although this method differs from those methods that
use patients to elicit utilities, it is a low-cost and efﬁcient way
with wide applicability of obtaining estimates of health value by
combining the best available scientiﬁc evidence with the collec-
tive judgment of experts. To calibrate the scale used by the expert
panelists with patient-derived estimates, we anchored the utility
scale used by panelists with patient ratings of different health
states. Ratings were elicited using a web tool; panelists made
independent initial ratings, met to discuss discrepancies, and then
rerated the clinical proﬁles. We used claims data to obtain cost
estimates. Details and steps are provided below and have been
reported in more detail elsewhere [15].
This article focuses solely on ratings for depression treatment
patterns by depression expert panelists. Because comparison of
cost-effectiveness across diseases can also be valuable, our
broader study included ratings for asthma treatments by asthma
expert panelists. To examine the extent to which raters from
different specialties would use the same underlying scale our
expert panelists each rated both depression and asthma proﬁles.
Past research suggests that a common, one-dimensional scale can
best be generated by using multispecialty panels that engage
in-group discussions after preliminary ratings [16]. A common
scale is necessary to directly compare ratings among different
health conditions and to evaluate trade-offs among different
treatments and conditions. Results reported elsewhere provide
support for the assumption that raters were using the same
underlying scale when rating each health condition [15].
Development of Clinical Proﬁles
The clinical proﬁle summarizes the critical information about
both the patient groups and the treatments to be rated and
includes anything that would affect either the before treatment
rating or the potential beneﬁt of a particular treatment. It speci-
ﬁes both the appropriate combinations of patient characteristics
and treatments and excludes treatments that are not clinically
relevant for particular patient groups. To create homogenous
patient proﬁles with respect to the value of treatment, we con-
ducted a literature review to identify the patient and illness
characteristics most likely to affect the average beneﬁt of treat-
ment. The literature review assessed age, sex, illness severity and
chronicity, and medical and substance use comorbidity. Based on
the review, we deﬁned three levels of depression severity (mild,
moderate, severe), using DSM-IV and two levels of chronicity
(acute, chronic) for adults between the ages of 18 and 55 years.
We deﬁned chronic depression as a major depressive episode that
has lasted more than 1 year. To create patient categories, we
crossed each level of depression severity with the two levels of
chronicity (six categories) and included an additional two cat-
egories of depression in partial remission and depression in full
remission. Thus, we obtained a total of eight different categories
of depression patients.
We deﬁned treatment patterns in the ﬁrst 4 months after an
initial visit that varied in terms of number of psychotherapy visits
(0, 1–3, 4–9, or 10 or more), use of a non-tricyclic antidepressant
(non-TCA) for more than 30 days (yes or no), whether the
patient received a medication follow-up visit (yes or no), and the
number of days of sedative/hypnotic use (0, 1–60, greater than
60). Because the number of potential treatment patterns is large
(a fully crossed design would have produced 48 different treat-
ment patterns, many of which were infrequently observed in the
claims data), we identiﬁed a subset of 18 common treatment
patterns that reﬂected approximately 95% of the patterns
observed in the claims data.
Medstat MarketScan medical and pharmacy claims for the
period 1998 to 2000 were used to identify patients between the
ages of 18 and 55 years with an initial visit for major depression
(N = 6343) and the most common depression treatment patterns
using ICD-9 codes. The Medstat MarketScan database includes
all inpatient, outpatient, and pharmacy claims, as well as enroll-
ment and demographic information for approximately 11
million covered lives. It includes employees, retirees, and depen-
dents from large, self-funded US employers. Although our litera-
ture review went through 2003, no new treatments for
depression were marketed between 2000 and 2003. We excluded
patients with any history of a bipolar or schizophrenia diagnosis.
An initial visit was deﬁned as the ﬁrst visit for a major depressive
episode after a 12-month period of no visits for depression, no
psychotherapy visits, and no antidepressant medication. Nonp-
harmaceutical treatments were deﬁned according to current pro-
cedural codes (CPT-4).
We crossed the 18 treatment patterns with the six patient
categories deﬁned by depression severity and chronicity
(N = 6 ¥ 18 = 108). We also included an additional three proﬁles
to address care for patients in full or partial remission for a total
of 111 clinical proﬁles to be rated. An additional 30% random
subset (N = 33) of patient treatment pattern combinations
included comorbid alcohol dependence (yes, no), major medical
illness (yes, no) or both. Experts rated a ﬁnal total of 144 clinical
proﬁles.
Expert Panel Methodology
We recruited six depression experts and seven asthma experts
from suggestions by highly regarded depression and asthma
researchers to participate in a single expert panel. Two panel
cochairs had expertise in both illnesses. All panelists were nation-
ally recognized as experts in their ﬁeld, and were active in both
clinical practice and research. In this article, estimates of health
value for depression treatments are based on ratings of depres-
sion experts. Depression expert panelists included psychiatrists,
primary care physicians, and psychologists. Before the meeting,
we provided all panelists with background information on health
value and a summary of patient reported utilities and quality of
life ratings for depression, asthma, and other conditions, from
the literature [17–20]. Information was graphically displayed on
a magnitude estimation “ruler” in which 0 represented death and
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1 represented the best possible health [15]. Project staff suggested
that panelists use the values provided in the ruler to anchor their
ratings.
Because pilot work had indicated that panelists often make
assumptions about the natural history of the illnesses when esti-
mating their ratings, we also provided them with key articles on
the natural history of depression and asthma, as well as recent
review articles and meta-analyses on treatment effectiveness and
a summary of the literature on patient characteristics that inﬂu-
ence treatment response. Articles were obtained by conducting a
MEDLINE and PsycINFO computerized searches of the English-
language literature through early 2003, supplemented with
searches of the Cochrane Database of Systematic Reviews.
All ratings were elicited using a web-based tool developed for
the project (http://web3.rand.org/equity/). This tool was designed
to enable raters to be consistent by providing summary informa-
tion and a table of the ratings just completed at the bottom of the
page. Panelists moved a cursor along a visual analogue scale that
ranged from 0 to 1 to make their ratings for each clinical proﬁle.
Deﬁnitions of the terms used to describe the different clinical
proﬁles were provided, either through a drop-down box or in
accompanying instructions. Panelists were ﬁrst asked to estimate
the health value of each clinical proﬁle before treatment (“before
treatment” ratings). We deﬁned health value as the preference for,
or desirability of a particular health outcome or health state [2].
Using the group average “before treatment” ratings as anchors,
panelists next estimated the health value of the same patient
groups after 3 months of no new treatment (“natural history”
ratings). We chose 3 months as the time horizon because most
acute treatment effects are seen within the ﬁrst 3 months of
treatment [21–23]. Panelists were then provided with informa-
tion on their own and others’ natural history ratings and were
encouraged to discuss with each other the basis for their ratings
during a conference call. Subsequently, panelists rerated the
natural history ratings for their own specialty. These were aver-
aged to produce the group average “natural history” rating.
Panelists then completed the “after treatment” ratings in
which they were asked to estimate the health value of a speciﬁed
treatment in a clinical proﬁle, 3 months after the treatment
began. For each clinical proﬁle, panelists were given both the
group average “before treatment” rating and the “natural
history” rating as anchors. The “after treatment” ratings formed
the basis of the discussion at the expert panel meeting (i.e.,
experts discussed discrepancies in an effort to reach consensus).
After the meeting, panelists rerated all the “after treatment”
ratings, although only estimates from the depression specialists
were used to calculate the ﬁnal ratings. Final rating results did
not signiﬁcantly change if nonspecialty ratings were included.
The health value of the treatment was deﬁned as the mean of the
“after treatment” rating minus the “natural history” rating.
Determination of Rating Reliability and Validity
Orlando et al. [15] provides a detailed analysis of the effects of
the expert panel meeting and the quality of the ﬁnal ratings. The
ﬁnal estimates possessed face validity (e.g., the relative value of
the ratings is ordered as expected from the clinical literature) and
had low variability (e.g., the standard deviations were consider-
ably lower than those reported in other studies). Analyses com-
paring initial and ﬁnal ratings showed that panelists were more in
agreement with each other and more consistent in their ratings
after the meeting.
Estimating Costs
Using the Medstat MarketScan data, we estimated costs for the
18 treatment patterns in the study. We selected all visits for which
major depression was a diagnosis and used the winsorized mean
costs, weighted by the frequency of the CPT-4 code. To obtain
psychotherapy costs, we ﬁrst calculated the average cost of both
an initial and follow-up psychotherapy visit. The cost of an initial
visit included weighted averages of CPT-4 new patient codes, as
well as psychotherapy codes. The cost of 10+ psychotherapy
visits was calculated as an initial psychotherapy visit added to 16
follow-up psychotherapy visits, as the literature provided to the
panelists suggested that this represents the low end of an optimal
number of visits [24–26]. We also calculated the average cost of
an initial medication evaluation visit, and a medication follow-up
visit.
We used pharmacy data to estimate the mean cost of a
3-month supply of a non-TCA, weighted by the frequency of the
type of antidepressant prescribed. The cost of treatment with an
antidepressant included both an initial medication evaluation
visit and a 3-month supply of medication.
Cost-Health Value Analyses
We ﬁrst describe the health value of common treatments for
depression in the United States by the chronicity and severity of
the depressive episode. To compare the health value and costs of
different patterns of care, we plotted cost-health value curves.
Results
Table 1 shows the most frequent treatment patterns for major
depression using claims data for individuals aged 18 to 55 years.
The ﬁrst and third most frequent treatment patterns—1 to 3 and
4 to 9 psychotherapy visits—are not consistent with clinical
guidelines [3] or the clinical effectiveness literature and only
2.9% represent combination treatment with both medications
and 10+ psychotherapy visits.
For each level of depression severity and chronicity, Figure 1
shows the health value (mean “after treatment” rating minus the
mean “natural history” rating) at 3 months of three alternative
treatments for major depression recommended by American Psy-
chiatric Association clinical guidelines→30 days antidepressant
treatments with at least one follow-up visit, 10 or more psycho-
therapy visits, or combination antidepressant and psychotherapy
treatment [3]. For mild depression, the health value of antidepres-
sants with medication follow-up is almost equivalent to 10+
psychotherapy visits. For severe depression (both acute and
Table 1 Frequency of usual-care treatment patterns for major depres-
sion in a privately insured population, aged 18 to 50 years, 1998 to 2000
Treatments % frequency (N)
1 to 3 psychotherapy visits 24.8 (1571)
4 to 9 psychotherapy visits 14.9 (942)
1 to 3 psychotherapy or ofﬁce based follow-up 13.3 (842)
visits and 30 days non-TCAs
4 to 9 psychotherapy- or ofﬁce-based follow-up 7.6 (481)
visits and 30 days non-TCAs
10+ psychotherapy visits 5.5 (350)
No treatment 4.9 (309)
10+ psychotherapy or ofﬁce based 2.9 (183)
follow-up visits and 30 days non-TCAs
30 days non-TCAs 2.5 (160)
1 to 3 psychotherapy or ofﬁce based follow-up 1.9 (123)
visits and 1 to 60 days of sedatives/hypnotics
Other* 21.8 (1382)
All treatments 100 (6343)
*Made up of over 50 other treatment patterns each of which has a prevalence of less than
1.9%.
TCA, tricyclic antidepressant.
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chronic), however, treatment with medication produces a larger
gain in health value than 10+ psychotherapy visits, with combi-
nation therapy producing the largest gains. For all severity levels,
combination treatmentwith psychotherapy and an antidepressant
produces the largest gains. Belowwe present some of our ﬁndings.
Figure 2 shows the 3-month costs and utilities of common
treatment patterns for acute mild major depression. Costs are
plotted on the horizontal axis and the health beneﬁt of each
treatment pattern is plotted on the vertical axis, using a (0, 1)
health value scale. On these curves, points that are to the left and
are higher represent treatments that are preferred because they
are either less expensive or produce the most beneﬁt for a given
cost than treatments represented by points which are below or to
the right. The ﬁgure is bounded on the horizontal axis by the
treatment with the lowest cost (1–3 therapy visits) and the
highest cost (10+ therapy visits, antidepressant medication and a
medication management follow-up visit). The Y-axis is anchored
by the treatment with the lowest health value for a given cost
(1–3 psychotherapy visits with no antidepressant medication
or medication follow-up), and the highest health value (10+
Figure 1 Three-month health value of alternative treatments for major depression.
Figure 2 The cost and health value of treatment for acute mild major depression.
Entries in parentheses represent:
Number of
psychotherapy visits
Received antidepressant
medication? Y or N?
Medication follow-up visit?
Y or N?
0 Y or N Y or N
1–3 Y or N Y or N
4–9 Y or N Y or N
10+ Y or N Y or N
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psychotherapy visits, >30 days of a non-TCA, and a medication
follow-up visit).
The graph shows that the lowest-cost treatment, 1 to 3 psy-
chotherapy visits, produces minimal health beneﬁt. Except for
this lowest-cost treatment and a medication visit without a
follow-up, treatments that include an antidepressant medication
with a medication follow-up produce more gain in health value
for a given cost (i.e., are more efﬁcient) than all other treatments.
Adding a medication follow-up visit to a treatment with an
antidepressant approximately doubles the health value of the
antidepressant for a minimal increase in cost. Adding psycho-
therapy to patients receiving both an antidepressant and a medi-
cation follow-up visit produces modest improvements in health
value but with signiﬁcantly higher costs. When taken in conjunc-
tion with the results from Table 1, Figure 2 shows that several
common treatment patterns (e.g., 4–9 psychotherapy visits or
1–3 psychotherapy visits with30 days of antidepressant and no
medication follow-up visit) cost more than other treatment pat-
terns that produce more beneﬁt at a lower cost.
Figures 3 and 4 show the data for acute moderate and acute
severe depression. The data for chronic depression are not shown
but are similar to those for acute depression. Because the mag-
nitude of improvement increases as the severity of the depressive
episode increases and the costs of treatment are the same across
the three severity levels, the largest gain in health value for a
given cost is obtained when treating the most ill patients.
Figure 3 The cost and health value of treatment for acute moderate major depression.
Entries in parentheses represent:
Number of
psychotherapy visits
Received antidepressant
medication? Y or N?
Medication follow-up visit?
Y or N?
0 Y or N Y or N
1–3 Y or N Y or N
4–9 Y or N Y or N
10+ Y or N Y or N
Figure 4 The cost and health value of treatment for acute severe major depression.
Entries in parentheses represent:
Number of
psychotherapy visits
Received antidepressant
medication? Y or N?
Medication follow-up visit?
Y or N?
0 Y or N Y or N
1–3 Y or N Y or N
4–9 Y or N Y or N
10+ Y or N Y or N
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We also obtained health value for a random sample of clinical
proﬁles that included comorbidities. We found that the impact of
comorbidity on health value was not constant across treatments
(data not shown), although in general the presence of comorbid-
ity reduced the beneﬁt of treatment.
Discussion
We report on a low-cost and efﬁcient method to estimate the
clinical beneﬁt of different patterns of care for major depression
in adults 18 to 55 years, using a common metric that permits
comparisons between and among conditions and treatments. We
also report 3-month costs of usual care treatment patterns. Our
results suggest where clinicians, administrators, and policymak-
ers can most efﬁciently target their efforts to improve usual care
for depression. Our approach takes a payer perspective, rather
than a broader societal perspective, consistent with efforts to
improve the quality and efﬁciency of health-care delivery.
Our ﬁndings regarding common treatment patterns conﬁrm
previous research ﬁndings: most adults with major depression are
not receiving recommended care in the ﬁrst 3 months after a new
treatment episode [4]. In our study, recommended care consistent
with the American Psychiatric Association clinical guidelines
would be represented by antidepressant treatment with a medi-
cation follow-up visit and/or at least 10 psychotherapy visits. The
most common treatment pattern was 1 to 3 psychotherapy visits
(25%), a treatment that our experts rated as minimally helpful,
followed by 4 to 9 psychotherapy visits (15%). Few received
guideline-concordant treatment: only 13% received antidepres-
sant treatment with 1 to 3 follow-up visits, and only 5.5%
received 10+ psychotherapy visits. Sixteen visits represent the
low end of the number of visits provided in most psychotherapy
effectiveness trials.
Our ﬁndings also show that most usual care treatment pat-
terns cost more than other treatment patterns that produce more
beneﬁt at a lower cost. This means that treatments with more
health beneﬁt could be provided for the same or less cost. The
clear implication is that there is no ﬁnancial reason to provide
care not recommended by clinical guidelines. The data also
suggest that for the less severe forms of depression, trade-offs
between medication and psychotherapy are small, and patient
preferences should be the major factor in choosing between two
comparable treatments. Nevertheless, for the more severely
depressed patients, there are strong cost-health value arguments
for recommending antidepressant treatment with 10+ psycho-
therapy visits.
The clinical and ﬁnancial implications of different patterns of
suboptimal care are poorly understood, but our methodology
can be used to estimate these. For example, we can use our cost
and health value data to calculate the incremental cost and
expected health value of increasing the average number of psy-
chotherapy visits from 2 to more than 10. Information about the
relative beneﬁts and costs of different practice patterns is crucial
when making trade-offs between costs and outcomes and to
guide choices toward the most efﬁcient methods for improving
health, given limited societal resources.
The data highlight that the health value of treatment is a
function of disease severity, with sicker individuals receiving
more health value from a given intervention. Because the cost
of a speciﬁed treatment remains the same for patients with dif-
ferent levels of disease severity, this implies that society will
receive the most health beneﬁt for the lowest cost when treating
sicker individuals. The data also suggest that adding a medica-
tion follow-up visit to an initial treatment visit at which an
antidepressant is prescribed produces a large gain in health
value for a relatively small incremental increase in costs over
and beyond antidepressant medication treatment without
follow-up.
Our approach builds upon two previous lines of research.
First, the method we use extends a previous approach used to
assess the appropriateness of care [14]. Using this approach,
expert panelists are asked to rate whether or not an intervention
is appropriate for patients with a speciﬁc set of indications and
where “appropriate” is deﬁned as health beneﬁts exceed health
risks. A modiﬁed expert panel approach has also been used to
estimate the magnitude of physician work associated with
various types of patient encounters reimbursed under Medicare
[16]. Our study is the ﬁrst of our knowledge to use expert panel
methods to obtain strongly consistent ratings of the magnitude of
health beneﬁts attributable to an intervention, using a generic
metric that can be compared between and among interventions.
To ensure that raters from different backgrounds were using the
scale in the same way, panelists rated both depression and asthma
clinical proﬁles. Although we do not present the asthma results
here, Orlando et al. [15] suggest that panelists were using the
same conceptual scale for both asthma and depression. This
means that our methodology could be applied to other condi-
tions as well, and, if valid, results could potentially be used to
make comparisons in health beneﬁt across conditions. We are
currently examining the question of comparability across other
conditions.
Second, our work also extends a previous approach to assess
value for depression care from the perspective of the health-care
system, referred to as “systems cost-effectiveness” [27,28]. This
method used expert panelists to estimate the health beneﬁts of
depression treatments using a disease-speciﬁc rating scale.
Results were applied to patterns of care and costs identiﬁed in
large administrative data sets from health plans to estimate the
incremental cost of achieving remission for a particular type of
depression case.
Our method is not intended to supplant formal CEA con-
ducted in association with clinical trials of pharmaceutical or
other treatment interventions. The rapidly expanding literature
providing results from formal CEAs based on recommended
approaches [2] will continue to provide key benchmarks for
establishing clinical recommendations, guidelines, and formulary
policies for depression and other medical conditions. Given the
requirements of such studies, relatively few cost-effectiveness
analyses for depression treatments are available in the literature
[29–33]. Our approach, like the “system cost-effectiveness”
work, provides an expert-based extrapolation from the clinical
trial evidence-base to the much wider array of care that is com-
monly delivered in usual practice. This extension to broader
health-care practices and populations can provide insight into
targets of opportunity for improving quality of usual care.
Because our target population included only adults 18 to 55
years, our results cannot be generalized to treatment for pediatric
or geriatric depression.
Our study has a number of limitations. Because raters were
asked to estimate overall health value regarding quality of life
improvements associated with health-care interventions, the
question arises of whose values are used to determine preference
for a health outcome. Current practice ranges from using the
health values of patients with the condition, to estimates from
health professionals or general community members. In our
study, we chose to use the values of health professionals from
both primary care and specialty care backgrounds, a choice made
to take advantage of clinician knowledge and experience regard-
ing the effectiveness of a variety of treatments in different treat-
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ment settings. As such, it does not take into account patient
treatment preferences. To anchor the expert ratings to patient
preferences, we provided clinicians with patient estimates of
utilities for different conditions and expect the expert ratings
to calibrate with patient-derived ratings. Clinicians were also
asked in their ratings to take into account side effects and other
issues that would reduce patient compliance with treatment
recommendations.
A second limitation is that our cost-health value analyses are
based on a 3-month time horizon, which may undervalue psy-
chotherapy relative to antidepressant treatment, as the cost of
antidepressant treatment extends over a longer time horizon. To
address this, we conducted additional cost-health value analyses,
in which we replaced 3-month costs with 12-month costs, and
used 3-month health value estimates as proxies for health value
at 12 months as the literature suggests that the effectiveness of
depression treatment remains relatively constant between 3 and
12 months [34–36]. For some clinical proﬁles, the most efﬁcient
treatment produced by these analyses includes psychotherapy
treatments without antidepressant medication.
A third limitation is that claims data are insufﬁcient to allow
us to understand why people are receiving the most common
treatment pattern, 1 to 3 psychotherapy visits. It is possible this
pattern represents people who fail to engage with psychotherapy
and for whom more visits would have a high beneﬁt, or it might
represent treatment for people whose symptoms have improved
with minimal psychotherapy. Understanding what this pattern
means would allow us to evaluate its value. Future research
should look at the reasons why the 1 to 3 psychotherapy visits is
the most prevalent pattern of treatment.
Reliance on claims data is also limiting in that we rely on
ICD-9 codes to identify patients in treatment for major depres-
sion. This reliance inevitably excludes some patients who may be
treated for depression but diagnosis not coded (e.g., in primary
care settings) and includes other patients who are coded for
major depression but may not fully meet criteria. Our results also
apply only to those people with access to care.
A ﬁnal limitation of our expert panel rating approach is that
we cannot fully address questions regarding its reproducibility,
because we have not had the opportunity to replicate the results
using a panel composed of different experts. Our study is there-
fore subject to the criticism that the particular composition of the
panel determined the results. Although previous studies suggest
that when the evidence base is strong, reproducibility of struc-
tured expert panel ratings is high [37,38], we note the many
clinical proﬁles for depression treatment where the evidence base
is weak or nonexistent. This is particularly true for the proﬁle of
receiving a medication follow-up visit, which the panel rated as
having a very substantial effect, but for which there is no research
evidence. It is not known whether having a medication follow-up
visit is important to support continued improvement or for
relapse prevention. Future studies should consider retesting this
method with a different expert panel to see whether the estimated
beneﬁts from treatment are reproducible.
Lastly, because drug costs have increased faster on average
than psychotherapy costs since 1998 to 2000, more recent data
on costs might narrow the differences in health value for the
treatment combinations that include drugs and those that include
only psychotherapy. Future studies should consider using cost
data from current claims data.
Our results suggest three targets for quality improvement
efforts related to making treatment for depression could be more
efﬁcient (e.g., cost less to get to a given outcome), a key compo-
nent of quality [1]. This is unusual, as generally improving treat-
ment outcomes adds costs. First, if the health beneﬁts for a
medication follow-up visit are as the panel estimated, the health
value from antidepressant treatment could be almost doubled
simply by increasing the proportion of people receiving a medi-
cation follow-up visit. Second, targeting effective treatments
toward the most severely ill increases value; early treatment may
prevent subsequent morbidity. Third, the most common treat-
ment pattern, 1 to 3 psychotherapy visits, produces minimal
health beneﬁt. For those people who continue to have symptoms
after 1 to 3 psychotherapy visits, adding an antidepressant medi-
cation or increasing the number of psychotherapy visits would
increase efﬁciency.
Source of ﬁnancial support: This research was conducted with ﬁnancial
support from the MacArthur Foundation Network on Mental Health
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Supplementary material for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
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